Lexeo Therapeutics (NASDAQ:LXEO) Trading Up 14.4%

Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) traded up 14.4% during trading on Thursday . The stock traded as high as $15.99 and last traded at $15.70. 92,795 shares were traded during trading, a decline of 14% from the average session volume of 107,916 shares. The stock had previously closed at $13.72.

Lexeo Therapeutics Trading Up 5.7 %

The business’s 50 day moving average is $13.83. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.21.

Lexeo Therapeutics (NASDAQ:LXEO) last released its earnings results on Monday, March 11th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.15). Equities analysts predict that Lexeo Therapeutics, Inc. will post -3.04 EPS for the current year.

Institutional Investors Weigh In On Lexeo Therapeutics

Several hedge funds have recently made changes to their positions in the company. Blackstone Inc. purchased a new stake in Lexeo Therapeutics in the 4th quarter worth approximately $9,342,000. Omega Fund Management LLC purchased a new stake in Lexeo Therapeutics in the 4th quarter worth approximately $28,955,000. Eventide Asset Management LLC purchased a new stake in Lexeo Therapeutics in the 4th quarter worth approximately $40,298,000. Cornell University acquired a new position in shares of Lexeo Therapeutics during the 1st quarter worth $1,980,000. Finally, BNP Paribas Financial Markets acquired a new position in shares of Lexeo Therapeutics during the 1st quarter worth $75,000. Hedge funds and other institutional investors own 60.67% of the company’s stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.